The Microbiome, Cancer, and Commercial Tests: Scientific Facts
In this article
Over the course of evolution, the human body has developed a symbiotic relationship with trillions of microorganisms. This ecosystem, called the ‘microbiota,’ does more than produce digestive enzymes: it governs vital functions such as training the immune system, creating barriers against pathogens, and regulating neuroendocrine signals. Over the past decade, advances in ‘Next-Generation Sequencing (NGS)’ technologies have enabled us to map this invisible world.
However, this scientific enlightenment has created a vast commercial market that regulation has yet to catch up with. Our patients now face hundreds of home test kits promising ‘personalized nutrition’ and probiotic supplements supported by weak scientific evidence. In this review, we analyze the validity of commercial tests, controversial clinical conditions such as SIBO (Small Intestinal Bacterial Overgrowth), and the microbiome’s crucial role in cancer treatment (the Oncobiome) in light of the latest literature.
Market Dynamics vs. Clinical Evidence: Is the Gap Widening?
*Note: Home microbiome tests are not currently recommended as standard diagnostic or monitoring tools in international cancer guidelines such as NCCN or ESMO.
Home Microbiome Tests: How Reliable Are They?
What Can They Do?
They provide a ‘snapshot’ of microbiome diversity (alpha/beta diversity). In severe dysbiosis (imbalance), they may help identify dietary shortcomings such as inadequate fiber. They are an ‘awareness tool.’
What Can They Not Do?
Diagnoses of Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), or Colon Cancer cannot be madeusing these tests. The results cannot be converted into a medical prescription stating, ‘You should take this probiotic.’
Commercial Risks
Many testing companies use report results as a ‘funnel’ to market their own probiotic or supplement brands. The concept of ‘personalized probiotics’ often lacks a scientific basis.
The SIBO Dossier: A Real Disease or a Commercial Label?
SIBO (Small Intestinal Bacterial Overgrowth), which has gained popularity in recent years, is an abnormally high bacterial count in the small intestine. However, this diagnosis remains controversial in medicine.
The small intestine normally contains far fewer bacteria than the colon. Stomach acid, bile, and intestinal movement (motility) keep this region clean. Diabetes, previous gastric surgery, or long-term proton pump inhibitor (stomach-protecting medication) use can disrupt this balance, allowing bacteria to migrate upward.
The diagnostic gold standard is ‘Jejunal Aspirate Culture’ (collecting fluid through endoscopy), but it is difficult. In practice, ‘Breath Tests’ (Lactulose/Glucose) are used. The problem is their high false-positive rate: there is a risk of diagnosing SIBO in someone who does not have it.
- SIBO is a real pathology but is less common than social media suggests.
- Not all bloating is SIBO; IBS, lactose intolerance, and visceral hypersensitivity are more common causes.
- Treatment requires not only antibiotics (Rifaximin) but also correction of the underlying cause (e.g., a motility disorder).
The Oncobiome: The Invisible Director of Cancer Treatment
Immune checkpoint inhibitors (anti-PD-1/PD-L1) have revolutionized cancer treatment. However, a substantial proportion of patients (40-60%) are resistant. Scientific data indicate that the gut microbiota is one of the main reasons for this resistance.
Molecular Mimicry and Cross-Reactivity: Some proteins on gut bacterial surfaces resemble tumor antigens. When the immune system recognizes these bacteria, it also learns to attack tumor cells through ‘cross-reactivity.’ Without healthy flora, this ‘immune training’ remains incomplete.
In Davar and colleagues’ study, patients with metastatic melanoma resistant to immunotherapy (Pembrolizumab) received fecal microbiota transplants (FMT) from patients showing a ‘super-response’ to treatment. The results were striking:
After transplantation, the patients’ gut flora shifted toward a ‘responder’ profile, immune combat cells infiltrated the tumor, and tumors began to shrink in 30-40% of resistant patients. This is the strongest evidence that the microbiome plays a ‘causal’ role in treatment success.
Friendly Bacteria: Studies show that higher levels of Akkermansia muciniphila, Faecalibacterium prausnitzii and Bifidobacterium species are associated with better survival and treatment response.
Pharmacomicrobiomics examines how bacteria ‘digest’ chemotherapy drugs. By secreting enzymes, bacteria can activate drugs (toxicity risk) or inactivate them (resistance risk).
| Drug | Microbiome Mechanism | Clinical Outcome |
|---|---|---|
| Cyclophosphamide | Modulates the intestinal barrier and triggers bacterial translocation (movement from the gut to lymphoid tissue). | Gram-positive bacteria (e.g., Enterococcus hirae) help the drug stimulate the immune system. Antibiotic use eliminates this effect. |
| Platinum Agents (Cisplatin) | Affects ROS (Reactive Oxygen Species) production in the tumor microenvironment. | Disrupted flora (dysbiosis) may reduce platinum agents’ ability to damage DNA. |
| Irinotecan | The bacterial enzyme beta-glucuronidase converts the inactive drug excreted from the liver back into its active form in the intestine. | The drug is not eliminated; it is reabsorbed and attacks intestinal cells, causing severe, life-threatening diarrhea . |
| Gemcitabine | In certain bacteria (e.g., Mycoplasma hyorhinis), cytidine deaminase breaks down the drug. | The presence of these bacteria within a pancreatic tumor causes the drug to be broken down before it can affect the tumor, leading to drug resistance. |
Cancer patients often turn to probiotics in an instinctive effort to ‘boost immunity.’ Oncology data, however, indicate that this approach can backfire.
A large analysis by MD Anderson Cancer Center involving melanoma patients receiving immunotherapy revealed a surprising finding:
Patients taking over-the-counter probiotics, compared with those not taking them, had a lower likelihood of responding to treatment and shorter survival.
Scientific Explanation: Commercial probiotics usually contain a limited range of bacterial species (*Lactobacillus*, *Bifidobacterium*). Taking large amounts of these ‘uniform’ bacteria externally may reduce intestinal ecological diversity (alpha diversity). Immunotherapy success, however, is associated with ‘rich and diverse’ rather than ‘uniform’ flora.
The tests in academic papers read by your doctor may not use the same technology as tests purchased online.
- 16S rRNA Sequencing (Common Commercial Test):
Examines only the bacterium’s ‘identity card’ (a gene region). It generally provides information at the genus level. Species and strain discrimination is weak. It cannot tell you what the bacterium does (its function). - Shotgun Metagenomics (Academic Standard):
Analyzes all DNA. It provides precise species- and strain-level discrimination (e.g., *E. coli Nissle 1917*). It can predict which genes bacteria carry and their potential metabolic functions (What can they do?).
The Metabolomics Gap: Neither DNA test directly measures the metabolites bacteria produce that exert the actual effects (short-chain fatty acids, secondary bile acids, etc.). This is like seeing only half the picture.
DROZDOGAN Academy Commentary
‘Microbiome research is among the most powerful and promising fields that will shape oncology’s future. However, we are currently in a “gray area” between scientific data generation (Discovery) and routine clinical application (Translation). No microbiome test has yet been approved as a biomarker that can tell us, “Give this patient this drug.”
An Evidence-Based Roadmap for Our Patients:
1. Approach to Testing: View commercial microbiome tests as tools for personal awareness and “biological curiosity,” rather than treatment guides. Never base treatment decisions solely on these reports.
2. Probiotic Warning: During cancer treatment (particularly immunotherapy), do not take arbitrary multistrain probiotic supplements unless your oncologist recommends them. Current data suggest that this could reduce diversity and harm treatment.
3. The Most Powerful Medicine: Diet: Manage your flora with food rather than pills. The safest proven way to increase diversity is a colorful diet rich in fiber (>20g daily), fermented foods (prebiotics), and polyphenols.’
Scientific References
- Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97-103.
- Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91-97.
- Davar D, Dulkadiroglu AK, Zarour HM, et al. Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients. Science. 2021;371(6529):595-602.
- Spencer CN, McQuade JL, Gopalakrishnan V, et al. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021;374(6575):1632-1640.
- Pimentel M, Saad RJ, Long MD, Rao SSC. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. Am J Gastroenterol. 2020;115(2):165-178.
- Baruch EN, Youngster I, Ben-Betzalel G, et al. Fecal microbiota transplantation for refractory metastatic melanoma. Science. 2021;371(6529):602-609.
- Sepich-Poore GD, Zitvogel L, Straussman R, et al. The microbiome and human cancer. Science. 2021;371(6536):eabc4552.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.